Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07266558 · ClinicalTrials.gov registry record · Phase 4
A Study to Evaluate the Efficacy and Safety of mRNA-1283 and mRNA-1273 in Participants 50 to 64 Years of Age Without High-Risk Conditions for Severe Coronavirus Disease 2019 (COVID-19)
A Phase 4 study of SARS-CoV-2, sponsored by ModernaTX.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 30,000
- Enrollment target
- 20
- Study locations
NCT07266558: Recruiting Phase 4 study of SARS-CoV-2, sponsored by ModernaTX.
NCT07266558 is a Phase 4 study of SARS-CoV-2 that is actively recruiting participants, run by ModernaTX. The registered enrollment target is 30,000 participants, above the 2,572-participant average among 34 other SARS-CoV-2 trials with a reported enrollment target (1066% higher). The trial reports 20 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07266558, a Phase 4 study of SARS-CoV-2, is actively recruiting participants, sponsored by ModernaTX.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 30,000 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate the efficacy and safety of mRNA-1283 and mRNA-1273 (variant formulations) in adults 50 to 64 years of age without high risk factors for severe COVID-19.
Primary Outcome
The VE is defined as the percent reduction in the hazard of the first event of symptomatic COVID-19 after study injection (each vaccine arm versus placebo) and will be estimated using 1-hazard ratio (HR).
Conditions Studied
Interventions
- BIOLOGICAL Placebo
- BIOLOGICAL mRNA-1273
- BIOLOGICAL mRNA-1283
Study Locations (20)
California
- Avacare - Colton
- CenExel CNR - Garden Grove
- Velocity Clinical Research, Huntington Park - Huntington Park
- Velocity Clinical Research - San Diego - ERN - PPDS-Site Number:8400010 - La Mesa
- Velocity Clinical Research - Los Angeles - Los Angeles
- Artemis Institute for Clinical Research - Riverside
- Peninsula Research Associates - Rolling Hills Estates
- Velocity Clinical Research -- Banning - San Bernardino
- Artemis Institute for Clinical Research - San Diego
Arizona
- Lenzmeier Family Medicine - Avacare - Glendale
- Desert Clinical Research - Mesa
- Velocity Clinical Research - Phoenix - Phoenix
- Foothills Research Center/Avacare - Phoenix
- Headlands Research Scottsdale - Scottsdale
- Fiel Family and Sports Medicine / Avacare - Tempe
Alabama
- Accel Clinical Research - Birmingham
- Cullman Clinical Trials - Cullman
- AMR Clinical Mobile - Mobile
- Velocity Clinical Research, Mobile - Mobile
Colorado
- Tekton Research, LLC - Denver
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30,000 participants |
| Start Date | 2025-11-26 |
| Est. Completion | 2027-06-16 |
| Phase | Phase 4 |
What NCT07266558 shows while recruiting
NCT07266558 is an interventional study that assigns participants to a tested intervention. Its 30,000 participants enrollment target places it among the larger protocols in the corpus, above the 2,572-participant average among 34 other SARS-CoV-2 trials with a reported enrollment target (1066% higher).
The record links to 1 condition, with SARS-CoV-2 appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT07266558 names 20 study sites across 4 states, led by California, Arizona, Alabama.
Frequently Asked Questions
What is clinical trial NCT07266558 about?
NCT07266558 is a clinical study titled "A Study to Evaluate the Efficacy and Safety of mRNA-1283 and mRNA-1273 in Participants 50 to 64 Years of Age Without High-Risk Conditions for Severe Coronavirus Disease 2019 (COVID-19)". The purpose of this study is to evaluate the efficacy and safety of mRNA-1283 and mRNA-1273 (variant formulations) in adults 50 to 64 years of age without high risk factors for severe COVID-19.
What is the current status of trial NCT07266558?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 30,000 participants. The study started on 2025-11-26. Estimated completion is 2027-06-16.
What conditions does trial NCT07266558 study?
This clinical trial studies the following conditions: SARS-CoV-2.
What interventions are being tested in trial NCT07266558?
The interventions under investigation include: Placebo (BIOLOGICAL), mRNA-1273 (BIOLOGICAL), mRNA-1283 (BIOLOGICAL).
Who is sponsoring clinical trial NCT07266558?
This trial is sponsored by ModernaTX, which has 90 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07266558 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for SARS-CoV-2
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07266558's enrollment target sits among peer trials
30,000 3rd of 34 higher than 32 of 34 other SARS-CoV-2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other SARS-CoV-2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Investigate the Immunogenicity and Safety of mRNA COVID-19 Variant-containing Vaccine Formulations
RECRUITING · Phase 4
-
Improving the Collaborative Health of Minority COVID-19 Survivor and Carepartner Dyads
RECRUITING · NA
-
Determinants of SARS (Severe Acute Respiratory Syndrome)-COV2 (COVID-19) Persistence After Convalescence
RECRUITING
-
Kisspeptin to Quantify GnRH Neuronal Function in Health and Disease
RECRUITING · Phase 1
-
Use and Effectiveness of COVID-19 Vaccines Using State Vaccine Registries and Insurance Claims Data
ACTIVE NOT RECRUITING
-
COVID-19 Biorepository
ACTIVE NOT RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00684580 · 30,000 participants
Protocol For Collecting Data On Patients With Childhood Cancer
- NCT03053193 · 30,000 participants
MammaPrint, BluePrint, and Full-genome Data Linked With Clinical Data to Evaluate New Gene EXpression Profiles
- NCT03689595 · 30,000 participants
Predicting Progression of Developing Myeloma in a High-Risk Screened Population (PROMISE)
- NCT04834869 · 30,000 participants
COVID-19 Vaccines Safety Tracking (CoVaST)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI